

USSN 09/871,339; Attorney Docket No. AREX-P02-005

In the claims:

1. **(Currently Amended)** A method for treating cancer comprising contacting a multi-epitopic tumor-associated antigen expressed in the serum with a composition comprising a binding reagent that specifically binds to a single first epitope on the tumor-associated antigen and allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, wherein whereby the formation of the reagent-antigen pair elicits a host immune response is elicited against a second epitope on the tumor-associated antigen.
2. **(Original)** The method of claim 1 wherein the binding reagent comprises a monoclonal antibody.
3. **(Currently Amended)** The method of claim 2 wherein the ~~target~~ multi-epitopic tumor associated antigen is CA 125.
4. **(Currently Amended)** The method of claim 2 wherein the ~~target~~ multi-epitopic tumor associated antigen is CA 19.9.
5. **(Currently Amended)** The method of claim 2 wherein the ~~target~~ multi-epitopic tumor associated antigen is CA15.3.
6. **(Original)** The method of claim 1 wherein the tumor-associated antigen is an ovarian tumor antigen.
7. **(Original)** The method of claim 1 wherein the host immune response is a cellular immune response.
8. **(Original)** The method of claim 1 wherein the host immune response is a humoral immune response.
9. **(Original)** The method of claim 1 wherein the host immune response is both a humoral immune response and a cellular response.

USSN 09/871,339; Attorney Docket No. AREX-P02-005

10. (Currently Amended) A method for eliciting a ~~as~~ therapeutic immune response comprising contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a first single epitope on the tumor-associated antigen; and allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, ~~whereby the formation of the reagent-antigen pair elicits wherein~~ a host immune response is elicited against a second epitope on the tumor-associated antigen.

11. (Currently Amended) A method for increasing the immunogenicity of an antigen comprising contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single first epitope on the tumor-associated antigen; and allowing the binding reagent to bind to the antigen to form a reagent-antigen pair; ~~whereby the formation of the reagent-antigen pair elicits wherein~~ a host immune response is elicited against a second epitope on the tumor-associated antigen.

12. (Currently Amended) A method for re-conforming a multi-epitopic tumor associated antigen expressed in a host serum and for recognizing and initiating an immune response, comprising contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single first epitope on the tumor-associated antigen; and allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, ~~whereby the formation of the reagent-antigen pair elicits wherein~~ a host immune response is elicited against a second epitope on the tumor associated antigen.

13-15. (Cancelled)

16. (New) A therapeutic composition comprising a binding agent specific for a first epitope on a multi-epitopic *in vivo* antigen present in a host's serum, which antigen does not elicit an effective host immune response, wherein the binding agent present in the composition specifically binds a first epitope on the antigen, forming a binding agent/antigen pair, whereby an effective host immune response is elicited against a second epitope on the antigen.